| Asphyxia (3) |  |
| Asthma (130) | |
| Dyspnea (3) | |
| Pneumonia (55) | |
| Pulmonary disease (4) | |
| Respiratory disease (3) | |
| Asphyxia (3) | |
| Asthma (130) | |
| Dyspnea (3) | |
| Pneumonia (55) | |
| Pulmonary disease (4) | |
| Respiratory disease (3) | |
and shortness of breath (dyspnea. e plan to submit these data to the FDA this year to support alectinib as a potential new option for people
or higher adverse event was shortness of breath (dyspnea; 4 percent. About the NP28761 Study NP28761 is a Phase I/II North american, single-arm, open-label,
5 percent) and shortness of breath (dyspnea; 3 percent. About Alectinib Alectinib (RG7853/AF-802/RO5424802/CH5424802) is an investigational oral medicine created at Chugai Kamakura Research Laboratories
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011